Evolution of extended-spectrum β-lactamases by mutation

Clinical Microbiology and Infection

Volumn 14, Issue SUPPL. 1, 2008, Pages 11-32

  Gniadkowski, M ^a  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

ESBL; Evolution; Mutation; Review; lactamase

Indexed keywords

ALANINE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ARGININE; ASPARTIC ACID; AZTREONAM; BACTERIAL DNA; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE TEM 1; CEFALORIDINE; CEFALOTIN; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN C; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; CYSTEINE; EXTENDED SPECTRUM BETA LACTAMASE; GLUTAMINE; GLYCINE; HISTIDINE; LEUCINE; PENICILLIN G; PIPERACILLIN; SERINE; TAZOBACTAM; TYROSINE; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL SURVIVAL; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; CONFORMATIONAL TRANSITION; CRYSTALLOGRAPHY; DNA MODIFICATION; DNA SEQUENCE; DRUG HYDROLYSIS; DRUG USE; ENTEROBACTERIACEAE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME STRUCTURE; EVOLUTION; GENE EXPRESSION; GENE MUTATION; GENE STRUCTURE; GENETIC RECOMBINATION; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; REVIEW;

BACTERIA (MICROORGANISMS); NEGIBACTERIA;

EID: 37349021516     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01854.x     Document Type: Review

References (151)

1. Li WH, ed. Molecular evolution. Sunderland: Sinauer Associates, 1997.
2. Beadle BM, Shoichet BK. Structural bases of stability-function tradeoffs in enzymes. J Mol Biol 2002; 321: 285-296.
3. Singer RS, Finch R, Wegener HC, Bywater R, Walters J, Lipsitch M. Antibiotic resistance-the interplay between antibiotic use in animals and human beings. Lancet Infect Dis 2003; 3: 47-51.
4. Martinez JL, Baquero F. Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother 2000; 44: 1771-1777.
5. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-1233.
6. Massova I, Mobashery S. Kinship and diversification of bacterial penicillin-binding proteins and β-lactamases. Antimicrob Agents Chemother 1998; 42: 1-17.
7. Bonnet R, Sampaio JL, Chanal C et al. A novel classA extended-spectrum β-lactamase (BES-1) in Serratia marcescens isolated in Brazil. Antimicrob Agents Chemother 2000; 44: 3061-3068.
8. Bonnet R. Growing group of extended-spectrum β-lactamases: The CTX-M enzymes. Antimicrob Agents Chemother 2004; 48: 1-14.
9. Chang FY, Siu LK, Fung CP, Huang MH, Ho M. Diversity of SHV and TEM β-lactamases in Klebsiella pneumoniae: Gene evolution in Northern Taiwan and two novel β-lactamases, SHV-25 and SHV-26. Antimicrob Agents Chemother 2001; 45: 2407-2413.
10. Baraniak A, Fiett J, Mrówka A, Walory J, Hryniewicz W, Gniadkowski M. Evolution of TEM-type extended-spectrum β-lactamases in clinical strains of the family Enterobacteriaceae in Poland. Antimicrob Agents Chemother 2005; 49: 1872-1880.
11. Orencia MC, Yoon JS, Ness JE, Stemmer WPC, Stevens RC. Predicting the emergence of antibiotic resistance by directed evolution and structural analysis. Nat Struct Biol 2001; 8: 238-242.
12. Ambler RP. The structure of β-lactamases. Phil Trans R Soc Lond B 1980; 289: 321-331.
13. Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-584.
14. Knox JR. Extended-spectrum and inhibitor-resistant TEM-type β-lactamases: Mutations, specificity, and three-dimensional structure. Antimicrob Agents Chemother 1995; 39: 2593-2601.
15. Medeiros AA. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin Infect Dis 1997; 24 (suppl 1): S19-S45.
16. Ford PJ, Avison MB. Evolutionary mapping of the SHV β-lactamase and evidence for two separate IS26-dependent bla SHV mobilization events from the Klebsiella pneumoniae chromosome. J Antimicrob Chemother 2004; 54: 69-75.
17. Huang W, Petrosino J, Hirsch M, Shenkin PS, Palzkill T. Amino-acid sequence determinants of β-lactamase structure and activity. J Mol Biol 1996; 258: 688-703.
18. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-951.
19. Jacoby GA, Munoz-Price LS. The new β-lactamases. N Engl J Med 2005; 352: 380-391.
20. Gniadkowski M. Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 2001; 7: 597-608.
21. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev 2005; 18: 657-686.
22. Matagne A, Lamotte-Brasseur J, Frére JM. Catalytic properties of classA β-lactamases: Efficiency and diversity. Biochem J 1998; 330: 581-598.
23. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315-317.
24. Kliebe C, Nies BA, Meyer JF, Tolxdorff-Neutzling RM, Wiedemann B. Evolution of plasmid-coded resistance to broad spectrum cephalosporins. Antimicrob Agents Chemother 1985; 28: 302-307.
25. Corkill JE, Cuevas LE, Gurgel RQ, Greensill J, Hart CA. SHV-27, a novel cefotaxime-hydrolysing β-lactamase, identified in Klebsiella pneumoniae isolates from a Brazilian hospital. J Antimicrob Chemother 2001; 47: 463-465.
26. Ma L, Alba J, Chang FY et al. Novel SHV-derived extended-spectrum β-lactamase, SHV-57, that confers resistance to ceftazidime but not cefazolin. Antimicrob Agents Chemother 2005; 49: 600-605.
27. Poirel L, Heritier C, Podglajen I, Sougakoff W, Gutmann L, Nordmann P. Emergence in Klebsiella pneumoniae of a chromosome-encoded SHV β-lactamase that compromises the efficacy of imipenem. Antimicrob Agents Chemother 2003; 47: 755-758.
28. Weber DA, Sanders CC, Bakken JS, Quinn JP. A novel chromosomal TEM derivative and alterations in outer membrane proteins together mediate selective ceftazidime resistance in Escherichia coli. J Infect Dis 1990; 162: 460-465.
29. Chanal C, Sirot D, Malaure H, Poupart M-C, Sirot J. Sequences of CAZ-3 and CTX-2 extended-spectrum β-lactamase genes. Antimicrob Agents Chemother 1994; 38: 2452-2453.
30. Mabilat C, Courvalin P. Development of 'oligotyping'for characterization and molecular epidemiology of TEM β-lactamases in members of the family Enterobacteriaceae. Antimicrob Agents Chemother 1990; 34: 2210-2216.
31. Rasheed JK, Jay C, Metchock B et al. Evolution of extended-spectrum β-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother 1997; 41: 647-653.
32. Kurokawa H, Yagi T, Shibata N, Shibayama K, Kamachi K, Arakawa Y. A new SHV-derived extended-spectrum β-lactamase (SHV-24) that hydrolyzes ceftazidime through a single-amino-acid substitution (D179G) in the Ω-loop. Antimicrob Agents Chemother 2000; 44: 1725-1727.
33. Essack SY, Hall LM, Pillay DG, McFadyen ML, Livermore DM. Complexity and diversity of Klebsiella pneumoniae strains with extended-spectrum β-lactamases isolated in 1994 and 1996 at a teaching hospital in Durban, South Africa. Antimicrob Agents Chemother 2001; 45: 88-95.
34. Cantón R, Oliver A, Coque TM, Varela MC, Pérez-Díaz JC, Baquero F. Epidemiology of extended-spectrum beta-lactamase-producing Enterobacter isolates in a Spanish hospital during a 12-year period. J Clin Microbiol 2002; 40: 1237-1243.
35. Cao V, Lambert T, Nhu DQ et al. Distribution of extended-spectrum β-lactamases in clinical isolates of Enterobacteriaceae in Vietnam. Antimicrob Agents Chemother 2002; 46: 3739-3743.
36. Mulvey MR, Bryce E, Boyd D et al. Ambler classA extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals. Antimicrob Agents Chemother 2004; 48: 1204-1214.
37. Juteršek B, Baraniak A, Zohar-Čretnik T, Storman A, Sadowy E, Gniadkowski M. Complex endemic situation regarding extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae in a hospital in Slovenia. Microb Drug Resist 2003; 9 (suppl 1): S25-S33.
38. Yuan M, Hall LM, Savelkoul PH, Vandenbroucke-Grauls CM, Livermore DM. SHV-13, a novel extended-spectrum β-lactamase, in Klebsiella pneumoniae isolates from patients in an intensive care unit in Amsterdam. Antimicrob Agents Chemother 2000; 44: 1081-1084.
39. Rasheed JK, Anderson GJ, Yigit H et al. Characterization of the extended-spectrum β-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC700603), which produces the novel enzyme SHV-18. Antimicrob Agents Chemother 2000; 44: 2382-2388.
40. Yigit H, Queenan AM, Anderson GJ et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45: 1151-1161.
41. Delmas J, Robin F, Bittar F, Chanal C, Bonnet R. Unexpected enzyme TEM-126: Role of mutation Asp179Glu. Antimicrob Agents Chemother 2005; 49: 4280-4287.
42. Blázquez J, Morosini MI, Negri MC, Baquero F. Selection of naturally occurring extended-spectrum TEM β-lactamase variants by fluctuating β-lactam pressure. Antimicrob Agents Chemother 2000; 44: 2182-2184.
43. Cantu C, Palzkill T. The role of residue238 of TEM-1 β-lactamase in the hydrolysis of extended-spectrum antibiotics. J Biol Chem 1998; 273: 26603-26609.
44. Wang X, Minasov G, Shoichet BK. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J Mol Biol 2002; 320: 85-95.
45. Nukaga M, Mayama K, Hujer AM, Bonomo RA, Knox JR. Ultrahigh resolution structure of a classA β-lactamase: On the mechanism and specificity of the extended-spectrum SHV-2 enzyme. J Mol Biol 2003; 328: 289-301.
46. Vakulenko SB, Taibi-Tronche P, Toth M, Massova I, Lerner SA, Mobashery S. Effects on substrate profile by mutational substitutions at positions164 and 179 of the classA TEM pUC19 β-lactamase from Escherichia coli. J Biol Chem 1999; 274: 23052-23060.
47. Hujer AM, Hujer KM, Helfand MS, Anderson VE, Bonomo RA. Amino-acid substitutions at Ambler position Gly238 in the SHV-1 beta-lactamase: exploring sequence requirements for resistance to penicillins and cephalosporins. Antimicrob Agents Chemother 2002; 46: 3971-3977.
48. Blázquez J, Morosini MI, Negri MC, Gonzalez-Leiza M, Baquero F. Single amino-acid replacements at positions altered in naturally occurring extended-spectrum TEM β-lactamases. Antimicrob Agents Chemother 1995; 39: 145-149.
49. Randegger CC, Keller A, Irla M, Wada A, Hächler H. Contribution of natural amino-acid substitutions in SHV extended-spectrum β-lactamases to resistance against various β-lactams. Antimicrob Agents Chemother 2000; 44: 2759-2763.
50. Huang W, Palzkill T. A natural polymorphism in β-lactamase is a global suppressor. Proc Natl Acad Sci USA 1997; 94: 8801-8806.
51. Palzkill T. β-Lactamases are changing their activity spectrums. ASM News 1998; 64: 90-94.
52. Raquet X, Vanhove M, Lamotte-Brasseur J, Goussard S, Courvalin P, Frére JM. Stability of TEM β-lactamase mutants hydrolyzing third generation cephalosporins. Proteins Struct Funct Genet 1995; 23: 63-72.
53. Sideraki V, Huang W, Palzkill T, Gilbert HF. A secondary drug resistance mutation of TEM-1 β-lactamase that suppresses misfolding and aggregation. Proc Natl Acad Sci USA 2001; 98: 283-288.
54. Palzkill T, Botstein D. Identification of amino-acid substitutions that alter the substrate specificity of TEM-1 β-lactamase. J Bacteriol 1992; 174: 5237-5243.
55. Palzkill T, Le Q, Venkatachalam KV, LaRocco M, Ocera H. Evolution of antibiotic resistance: Several different amino-acid substitutions in an active site loop alter the substrate profile of β-lactamase. Mol Microbiol 1994; 12: 217-229.
56. Hernández-Allés S, Conejo MC, Pascual A, Tomás JM, BenedíVJ, Martínez-Martínez L. Relationship between outer membrane alterations and susceptibility to antimicrobial agents in isogenic strains of Klebsiella pneumoniae. J Antimicrob Chemother 2000; 46: 273-277.
57. Crowley B, BenedíVJ, Doménech-Sánchez A. Expression of SHV-2 β-lactamase and of reduced amounts of OmpK36 porin in Klebsiella pneumoniae results in increased resistance to cephalosporins and carbapenems. Antimicrob Agents Chemother 2002; 46: 3679-3682.
58. Doménech-Sánchez A, Martínez-Martínez L, Hernández-Allés S et al. Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother 2003; 47: 3332-3335.
59. Chen ST, Clowes R. Two improved promoter sequences for the beta-lactamase expression arising from a single base-pair substitution. Nucleic Acids Res 1984; 12: 3219-3234.
60. Chen ST, Clowes R. Variations between the nucleotide sequences of Tn1, Tn2, and Tn3 and expression of β-lactamase in Pseudomonas aeruginosa and Escherichia coli. J Bacteriol 1987; 169: 913-916.
61. Goussard S, Sougakoff W, Mabilat C, Bauernfeind A, Courvalin P. An IS1-like element is responsible for high-level synthesis of extended-spectrum β-lactamase TEM-6 in Enterobacteriaceae. J Gen Microbiol 1991; 137: 2681-2687.
62. Mabilat C, Goussard S, Sougakoff W, Spencer RC, Courvalin P. Direct sequencing of the amplified structural gene and promoter for the extended-broad-spectrum β-lactamase TEM-9 (RHH-1) of Klebsiella pneumoniae. Plasmid 1990; 23: 1-8.
63. Pałucha A, Mikiewicz B, Gniadkowski M. Diversification of Escherichia coli expressing an SHV-type extended-spectrum β-lactamase (ESBL) during a hospital outbreak: Emergence of an ESBL-hyperproducing strain resistant to expanded-spectrum cephalosporins. Antimicrob Agents Chemother 1999; 43: 393-396.
64. Lefort A, Arlet G, Join-Lambert OF, Lecuit M, Lortholary O. Novel extended-spectrum β-lactamase in Shigella sonnei. Emerg Infect Dis 2007; 13: 653-654.
65. Mazzariol A, Roelofsen E, Koncan R, Voss A, Cornaglia G. Detection of a new SHV-type extended-spectrum β-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands. Antimicrob Agents Chemother 2007; 51: 1082-1084.
66. Sowek JA, Singer SB, Ohringer S et al. Substitution of lysine at position104 or 240 of TEM-1 pTZ18R β-lactamase enhances the effect of serine-164 substitution on hydrolysis or affinity for cephalosporins and the monobactam aztreonam. Biochemistry 1991; 30: 3179-3188.
67. Venkatachalam KV, Huang W, LaRocco M, Palzkill T. Characterization of TEM-1 β-lactamase mutants from positions238 to 241 with increased catalytic efficiency for ceftazidime. J Biol Chem 1994; 269: 23444-23450.
68. Bradford PA, Cherubin CE, Idemyor V, Rasmussen BA, Bush K. Multiply resistant Klebsiella pneumoniae from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing β-lactamases in a single isolate. Antimicrob Agents Chemother 1994; 38: 761-766.
69. Gniadkowski M, Schneider I, Jungwirth R, Hryniewicz W, Bauernfeind A. Ceftazidime-resistant Enterobacteriaceae isolates from three Polish hospitals: Identification of three novel TEM- and SHV-5-type extended-spectrum β-lactamases. Antimicrob Agents Chemother 1998; 42: 514-520.
70. Billot-Klein D, Gutmann L, Collatz E. Nucleotide sequence of the SHV-5 β-lactamase gene of a Klebsiella pneumoniae plasmid. Antimicrob Agents Chemother 1990; 34: 2439-2441.
71. Rosenau A, Cattier B, Gousset N, Harriau P, Philippon A, Quentin R. Capnocytophaga ochracea: Characterization of a plasmid-encoded extended-spectrum TEM-17 β-lactamase in the phylum Flavobacter-Bacteroides. Antimicrob Agents Chemother 2000; 44: 760-762.
72. Neuwirth C, Labia R, Siebor E et al. Characterization of TEM-56, a novel β-lactamase produced by a Klebsiella pneumoniae clinical isolate. Antimicrob Agents Chemother 2000; 44: 453-455.
73. Quinn JP, Miyashiro D, Sahm D, Flamm R, Bush K. Novel plasmid-mediated β-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1989; 33: 1451-1456.
74. Naumovski L, Quinn JP, Miyashiro D et al. Outbreak of ceftazidime resistance due to a novel extended-spectrum β-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 1992; 36: 1991-1996.
75. Rasheed JK, Anderson GJ, Queenan AM et al. TEM-71, a novel plasmid-encoded, extended-spectrum β-lactamase produced by a clinical isolate of Klebsiella pneumoniae. Antimicrob Agents Chemother 2002; 46: 2000-2003.
76. Rice LB, Willey SH, Papanicolaou GA et al. Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 1990; 34: 2193-2199.
77. Jacoby GA, Carreras I. Activities of β-lactam antibiotics against Escherichia coli strains producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 1990; 34: 858-862.
78. Bradford PA, Jacobus NV, Bhachech N, Bush K. TEM-28 from an Escherichia coli clinical isolate is a member of the His-164 family of TEM-1 extended-spectrum β-lactamases. Antimicrob Agents Chemother 1996; 40: 260-262.
79. De Champs C, Sirot D, Chanal C, Bonnet R, Sirot J; the French Study Group. A 1998 survey of extended-spectrum β-lactamases in Enterobacteriaceae in France. Antimicrob Agents Chemother 2000; 44: 3177-3179.
80. Urban C, Meyer KS, Mariano N et al. Identification of TEM-26 β-lactamase responsible for a major outbreak of ceftazidime-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 1994; 38: 392-395.
81. Perilli M, Dell'Amico E, Segatore B et al. Molecular characterization of extended-spectrum β-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey. J Clin Microbiol 2002; 40: 611-614.
82. Hernández JR, Martínez-Martínez L, Cantón R, Coque TM, Pascual A; Spanish Group for Nosocomial Infections (GEIH). Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases in Spain. Antimicrob Agents Chemother 2005; 49: 2122-2125.
83. Chaves J, Ladona MG, Segura C, Coira A, Reig R, Ampurdanes C. SHV-1 β-lactamase is mainly a chromosomally encoded species-specific enzyme in Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45: 2856-2861.
84. Arpin C, Dubois V, Coulange L et al. Extended-spectrum β-lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother 2003; 47: 3506-3514.
85. Nicolas MH, Jarlier V, Honore N, Philippon A, Cole ST. Molecular characterization of the gene encoding SHV-3 β-lactamase responsible for transferable cefotaxime resistance in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1989; 33: 2096-2100.
86. Peduzzi J, Barthlmy M, Tiwari K, Mattioni D, Labia R. Structural features related to hydrolytic activity against ceftazidime of plasmid-mediated SHV-type CAZ-5 β-lactamase. Antimicrob Agents Chemother 1989; 33: 2160-2163.
87. Arlet G, Goussard S, Courvalin P, Philippon A. Sequences of the genes for the TEM-20, TEM-21, TEM-22, and TEM-29 extended-spectrum β-lactamases. Antimicrob Agents Chemother 1999; 43: 969-971.
88. Blázquez J, Negri MC, Morosini MI, Gómez-Gómez JM, Baquero F. A237T as a modulating mutation in naturally occurring extended-spectrum TEM-type β-lactamases. Antimicrob Agents Chemother 1998; 42: 1042-1044.
89. Chanal-Claris C, Sirot D, Bret L, Chatron P, Labia R, Sirot J. Novel extended-spectrum-type β-lactamase from an Escherichia coli isolate resistant to ceftazidime and susceptible to cephalotin. Antimicrob Agents Chemother 1997; 41: 715-716.
90. Healey WJ, Labgold MR, Richards JH. Substrate specificities in classA β-lactamases: Preference for penams vs. cephems. The role of residue237. Proteins 1989; 6: 275-283.
91. Yang Y, Bhachech N, Bradford PA, Jett BD, Sahm DF, Bush K. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli isolates producing TEM-10 and TEM-43 β-lactamases from St Louis, Missouri. Antimicrob Agents Chemother 1998; 42: 1671-1676.
92. Poyart C, Mugnier R, Quesnes G, Berche R, Trieu-Cuot P. A novel extended-spectrum TEM-type β-lactamases (TEM-52) associated with decreased susceptibility to moxalactam in Klebsiella pneumoniae. Antimicrob Agents Chemother 1998; 42: 108-113.
93. Mugnier P, Dubrous P, Casin I, Arlet G, Collatz E. A TEM-derived extended-spectrum β-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 2488-2493.
94. Caporale B, Franceschini N, Perilli M, Segatore B, Rossolini GM, Amicosante G. Biochemical characterization of laboratory mutants of extended-spectrum β-lactamase TEM-60. Antimicrob Agents Chemother 2004; 48: 3579-3582.
95. Nicolas-Chanoine MH. Inhibitor-resistant β-lactamases. J Antimicrob Chemother 1997; 40: 1-3.
96. ChaïbïEB, Sirot D, Paul G, Labia R. Inhibitor-resistant TEM β-lactamases: Phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother 1999; 43: 447-458.
97. Farzaneh S, Chaïbï EB, Peduzzi J et al. Implication of Ile-69 and Thr-182 residues in kinetic characteristics of IRT-3 (TEM-32) β-lactamase. Antimicrob Agents Chemother 1996; 40: 2434-2436.
98. Vakulenko SB, Geryk B, Kotra LP, Mobashery S, Lerner SA. Selection and characterization of β-lactam-β-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 β-lactamase gene. Antimicrob Agents Chemother 1998; 42: 1542-1548.
99. Sirot D, Recule C, Chaibi EB et al. A complex mutant of TEM-1 β-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate. Antimicrob Agents Chemother 1997; 41: 1322-1325.
100. Fiett J, Pałucha A, Mia̧czyńska B et al. A novel complex mutant β-lactamase, TEM-68, identified in a Klebsiella pneumoniae isolate from an outbreak of extended-spectrum β-lactamase-producing klebsiellae. Antimicrob Agents Chemother 2000; 44: 1499-1505.
101. Neuwirth C, Madec S, Siebor E et al. TEM-89 β-lactamase produced by a Proteus mirabilis clinical isolate: New complex mutant (CMT3) with mutations in both TEM-59 (IRT-17) and TEM-3. Antimicrob Agents Chemother 2001; 45: 3591-3594.
102. Robin F, Delmas J, Chanal C, Sirot D, Sirot J, Bonnet R. TEM-109 (CMT-5), a natural complex mutant of TEM-1 β-lactamase combining the amino-acid substitutions of TEM-6 and TEM-33 (IRT-5). Antimicrob Agents Chemother 2005; 49: 4443-4447.
103. Poirel L, Mammeri H, Nordmann P. TEM-121, a novel complex mutant of TEM-type β-lactamase from Enterobacter aerogenes. Antimicrob Agents Chemother 2004; 48: 4528-4531.
104. Robin F, Delmas J, Archambaud M, Schweitzer C, Chanal C, Bonnet R. CMT-type β-lactamase TEM-125, an emerging problem for extended-spectrum β-lactamase detection. Antimicrob Agents Chemother 2006; 50: 2403-2408.
105. Prinarakis EE, Miriagou V, Tzelepi E, Gazouli M, Tzouvelekis LS. Emergence of an inhibitor-resistant β-lactamase (SHV-10) derived from an SHV-5 variant. Antimicrob Agents Chemother 1997; 41: 838-840.
106. Robin F, Delmas J, Schweitzer C et al. Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. Antimicrob Agents Chemother 2007; 51: 1304-1309.
107. Stapleton PD, Shannon KP, French GL. Construction and characterization of mutants of the TEM-1 β-lactamase containing amino-acid substitutions associated with both extended-spectrum resistance and resistance to β-lactamase inhibitors. Antimicrob Agents Chemother 1999; 43: 1881-1887.
108. Giakkoupi P, Miriagou V, Gazouli M, Tzelepi E, Legakis NJ, Tzouvelekis LS. Properties of mutant SHV-5 beta-lactamases constructed by substitution of isoleucine or valine for methionine at position69. Antimicrob Agents Chemother 1998; 42: 1281-1283.
109. Giakkoupi P, Tzelepi E, Legakis NJ, Tzouvelekis LS. Aspartic acid for asparagine substitution at position276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 β-lactamases. J Antimicrob Chemother 1999; 43: 23-29.
110. Giakkoupi P, Tzelepi E, Tassios PT, Legakis NJ, Tzouvelekis LS. Detrimental effect of the combination of R164S with G238S in TEM-1 beta-lactamase on the extended-spectrum activity conferred by each single mutation. J Antimicrob Chemother 2000; 45: 101-104.
111. Chanal C, Poupart MC, Sirot D, Labia R, Sirot J, Cluzel R. Nucleotide sequences of CAZ-2, CAZ-6, and CAZ-7 β-lactamase genes. Antimicrob Agents Chemother 1992; 36: 1817-1820.
112. Stemmer WP. Rapid evolution of a protein invitro by DNA shuffling. Nature 1994; 370: 389-391.
113. Zaccolo M, Gherardi E. The effect of high-frequency random mutagenesis on invitro protein evolution: A study on TEM-1 β-lactamase. J Mol Biol 1999; 285: 775-783.
114. Hall BG. Predicting evolution by invitro evolution requires determining evolutionary pathways. Antimicrob Agents Chemother 2002; 46: 3035-3038.
115. Weinreich DM, Delaney NF, Depristo MA, Hartl DL. Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 2006; 312: 111-114.
116. Bauernfeind A, Stemplinger I, Jungwirth R, Ernst S, Casellas NM. Sequences of β-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino-acid sequences with those of other β-lactamases. Antimicrob Agents Chemother 1996; 40: 509-513.
117. Nordmann P, Naas T. Sequence analysis of PER-1 extended-spectrum β-lactamase from Pseudomonas aeruginosa and comparison with classA β-lactamases. Antimicrob Agents Chemother 1994; 38: 104-114.
118. Poirel L, Naas T, Guibert M, Chaibi EB, Labia R, Nordmann P. Molecular and biochemical characterization of VEB-1, a novel classA extended-spectrum β-lactamase encoded by an Escherichia coli integron gene. Antimicrob Agents Chemother 1999; 43: 573-581.
119. Poirel L, Le Thomas I, Naas T, Karim A, Nordmann P. Biochemical sequence analyses of GES-1, a novel classA extended-spectrum β-lactamase, and the class1 integron In 52 from Klebsiella pneumoniae. Antimicrob Agents Chemother 2000; 44: 622-632.
120. Silva J, Aguilar C, Ayala G et al. TLA-1: A new plasmid-mediated extended-spectrum β-lactamase from Escherichia coli. Antimicrob Agents Chemother 2000; 44: 997-1003.
121. Matsumoto Y, Inoue M. Characterization of SFO-1, a plasmid-mediated inducible classA β-lactamase from Enterobacter cloacae. Antimicrob Agents Chemother 1999; 43: 307-313.
122. Poirel L, Brinas L, Verlinde A, Ide L, Nordmann P. BEL-1, a novel clavulanic acid-inhibited extended-spectrum β-lactamase, and the class1 integron In120 in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 3743-3748.
123. Tzouvelekis LS, Tzelepi E, Tassios PT, Legakis NJ. CTX-M-type β-lactamases: An emerging group of extended-spectrum enzymes. Int J Antimicrob Agents 2000; 14: 137-142.
124. Navarro F, Miró E. Update on CTX-M-type β-lactamases. Rev Med Microbiol 2002; 13: 63-73.
125. Oliver A, Pérez-Díaz JC, Coque TM, Baquero F, Cantón R. Nucleotide sequence and characterization of a novel cefotaxime-hydrolyzing β-lactamase (CTX-M-10) isolated in Spain. Antimicrob Agents Chemother 2001; 45: 616-620.
126. Humeniuk C, Arlet G, Gautier V, Grimont P, Labia R, Philippon A. β-Lactamases of Kluyvera ascorbata, probable progenitors of some plasmid-encoded CTX-M types. Antimicrob Agents Chemother 2002; 46: 3045-3049.
127. Poirel L, Kampfer P, Nordmann P. Chromosome-encoded Ambler classA β-lactamase of Kluyvera georgiana, a probable progenitor of a subgroup of CTX-M extended-spectrum β-lactamases. Antimicrob Agents Chemother 2002; 46: 4038-4040.
128. Rodríguez MM, Power P, Radice M et al. Chromosome-encoded CTX-M-3 from Kluyvera ascorbata: A possible origin of plasmid-borne CTX-M-1-derived cefotaximases. Antimicrob Agents Chemother 2004; 48: 4895-4897.
129. Olson AB, Silverman M, Boyd DA et al. Identification of a progenitor of the CTX-M-9 group of extended-spectrum β-lactamases from Kluyvera georgiana isolated in Guyana. Antimicrob Agents Chemother 2005; 49: 2112-2115.
130. Shimamura T, Ibuka A, Fushinobu S et al. Acyl-intermediate structures of the extended-spectrum classA β-lactamase, Toho-1, in complex with cefotaxime, cephalothin, and benzylpenicillin. J Biol Chem 2002; 277: 46601-46608.
131. Chen Y, Delmas J, Sirot J, Shoichet B, Bonnet R. Atomic resolution structures of CTX-M β-lactamases: Extended spectrum activities from increased mobility and decreased stability. J Mol Biol 2005; 348: 349-362.
132. Gazouli M, Tzelepi E, Sidorenko SV, Tzouvelekis LS. Sequence of the gene encoding a plasmid-mediated cefotaxime-hydrolyzing classA β-lactamase (CTX-M-4): Involvement of serine237 in cephalosporin hydrolysis. Antimicrob Agents Chemother 1998; 42: 1259-1262.
133. Karim A, Poirel L, Nagarajan S, Nordmann P. Plasmid-mediated extended-spectrum β-lactamase (CTX-M-3 like) from India and gene association with insertion sequence IS Ecp1. FEMS Microbiol Lett 2001; 201: 237-241.
134. Bonnet R, Dutour C, Sampaio JL et al. Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240→ Gly. Antimicrob Agents Chemother 2001; 45: 2269-2275.
135. Munday CJ, Boyd DA, Brenwald N et al. Molecular and kinetic comparison of the novel extended-spectrum β-lactamases CTX-M-25 and CTX-M-26. Antimicrob Agents Chemother 2004; 48: 4829-4834.
136. Bonnet R, Recule C, Baraduc R et al. Effect of D240G substitution in a novel ESBL CTX-M-27. J Antimicrob Chemother 2003; 52: 29-35.
137. Cartelle M, del Mar Tomas M, Molina F, Moure R, Villanueva R, Bou G. High-level resistance to ceftazidime conferred by a novel enzyme, CTX-M-32, derived from CTX-M-1 through a single Asp240-Gly substitution. Antimicrob Agents Chemother 2004; 48: 2308-2313.
138. Poirel L, Naas T, Le Thomas I, Karim A, Bingen E, Nordmann P. CTX-M-type extended-spectrum β-lactamase that hydrolyzes ceftazidime through a single amino-acid substitution in the omega loop. Antimicrob Agents Chemother 2001; 45: 3355-3361.
139. Stürenburg E, Kuhn A, Mack D, Laufs R. A novel extended-spectrum β-lactamase CTX-M-23 with a P167T substitution in the active-site omega loop associated with ceftazidime resistance. J Antimicrob Chemother 2004; 54: 406-409.
140. Poirel L, Gniadkowski M, Nordmann P. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum β-lactamase CTX-M-15 and of its structurally related β-lactamase CTX-M-3. J Antimicrob Chemother 2003; 50: 1031-1034.
141. Welsh KJ, Barlow M, Tenover FC et al. Experimental prediction of the evolution of ceftazidime resistance in the CTX-M-2 extended-spectrum β-lactamase. Antimicrob Agents Chemother 2005; 49: 1242-1244.
142. Delmas J, Robin F, Carvalho F, Mongaret C, Bonnet R. Prediction of the evolution of ceftazidime resistance in extended-spectrum β-lactamase CTX-M-9. Antimicrob Agents Chemother 2006; 50: 731-738.
143. Mammeri H, Poirel L, Nordmann P. Invivo selection of a chromosomally encoded β-lactamase variant conferring ceftazidime resistance in Klebsiella oxytoca. Antimicrob Agents Chemother 2003; 47: 3739-3742.
144. Lee SH, Jeong SH. Nomenclature of GES-type extended-spectrum β-lactamases. Antimicrob Agents Chemother 2005; 49: 2148-2150.
145. Giakkoupi P, Tzouvelekis LS, Tsakris A, Loukova V, Sofianou D, Tzelepi E. IBC-1, a novel integron-associated classA β-lactamase with extended-spectrum properties produced by an Enterobacter cloacae clinical strain. Antimicrob Agents Chemother 2000; 44: 2247-2253.
146. Poirel L, Weldhagen GF, Naas T, De Champs C, Dove MG, Nordmann P. GES-2, a classA β-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob Agents Chemother 2001; 45: 2598-2603.
147. Wachino J, Doi Y, Yamane K et al. Nosocomial spread of ceftazidime-resistant Klebsiella pneumoniae strains producing a novel classa β-lactamase, GES-3, in a neonatal intensive care unit in Japan. Antimicrob Agents Chemother 2004; 48: 1960-1967.
148. Duarte A, Boavida F, Grosso F et al. Outbreak of GES-1 β-lactamase-producing multidrug-resistant Klebsiella pneumoniae in a university hospital in Lisbon, Portugal. Antimicrob Agents Chemother 2003; 47: 1481-1482.
149. Wachino J, Doi Y, Yamane K et al. Molecular characterization of a cephamycin-hydrolyzing and inhibitor-resistant classA β-lactamase, GES-4, possessing a single G170S substitution in the Ω-loop. Antimicrob Agents Chemother 2004; 48: 2905-2910.
150. Vourli S, Giakkoupi P, Miriagou V, Tzelepi E, Vatopoulos AC, Tzouvelekis LS. Novel GES/IBC extended-spectrum β-lactamase variants with carbapenemase activity in clinical enterobacteria. FEMS Microbiol Lett 2004; 234: 209-213.
151. Baquero MR, Galán JC, Turrientes MC et al. Increased mutation frequencies in Escherichia coli isolates harboring extended-spectrum β-lactamases. Antimicrob Agents Chemother 2005; 49: 4754-4756.